Researchmoz added Most up-to-date research on "Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018" to its huge collection of research reports.
This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3).
It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for RSV and HPIV-3 infections, and features dormant and discontinued products.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1763913
RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat.
Scope
- Which companies are the most active within the pipeline for RSV and HPIV-3 infections?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 8
2.1 GBI Research Report Coverage 8
2.2 Respiratory Syncytial Virus (RSV) Infections Overview 8
2.3 Human Parainfluenza Virus 3 Infections Overview 8
3 Therapeutics Development 9
3.1 Respiratory Syncytial Virus (RSV) Infections 9
3.2 Human Parainfluenza Virus 3 Infections 22
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/respiratory-syncytial-virus-and-human-parainfluenza-virus-3-infections-drug-development-pipeline-review-2018-report.html/toc
4 Therapeutics Assessment 25
4.1 Respiratory Syncytial Virus (RSV) Infections 25
4.2 Human Parainfluenza Virus 3 Infections 31
5 Companies Involved in Therapeutics Development 38
5.1 Respiratory Syncytial Virus (RSV) Infections 38
5.2 Human Parainfluenza Virus 3 Infections 61
6 Dormant Projects 63
6.1 Respiratory Syncytial Virus (RSV) Infections 63
6.2 Human Parainfluenza Virus 3 Infections 67
7 Discontinued Products 68
7.1 Respiratory Syncytial Virus (RSV) Infections 68
7.2 Human Parainfluenza Virus 3 Infections 68
8 Product Development Milestones 69
8.1 Respiratory Syncytial Virus (RSV) Infections 69
9 Appendix 81
9.1 Methodology 81
9.2 Coverage 81
9.3 Secondary Research 81
9.4 Primary Research 81
9.5 Expert Panel Validation 81
9.6 Contact Us 82
9.7 Disclaimer 82
This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3).
It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for RSV and HPIV-3 infections, and features dormant and discontinued products.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1763913
RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat.
Scope
- Which companies are the most active within the pipeline for RSV and HPIV-3 infections?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 8
2.1 GBI Research Report Coverage 8
2.2 Respiratory Syncytial Virus (RSV) Infections Overview 8
2.3 Human Parainfluenza Virus 3 Infections Overview 8
3 Therapeutics Development 9
3.1 Respiratory Syncytial Virus (RSV) Infections 9
3.2 Human Parainfluenza Virus 3 Infections 22
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/respiratory-syncytial-virus-and-human-parainfluenza-virus-3-infections-drug-development-pipeline-review-2018-report.html/toc
4 Therapeutics Assessment 25
4.1 Respiratory Syncytial Virus (RSV) Infections 25
4.2 Human Parainfluenza Virus 3 Infections 31
5 Companies Involved in Therapeutics Development 38
5.1 Respiratory Syncytial Virus (RSV) Infections 38
5.2 Human Parainfluenza Virus 3 Infections 61
6 Dormant Projects 63
6.1 Respiratory Syncytial Virus (RSV) Infections 63
6.2 Human Parainfluenza Virus 3 Infections 67
7 Discontinued Products 68
7.1 Respiratory Syncytial Virus (RSV) Infections 68
7.2 Human Parainfluenza Virus 3 Infections 68
8 Product Development Milestones 69
8.1 Respiratory Syncytial Virus (RSV) Infections 69
9 Appendix 81
9.1 Methodology 81
9.2 Coverage 81
9.3 Secondary Research 81
9.4 Primary Research 81
9.5 Expert Panel Validation 81
9.6 Contact Us 82
9.7 Disclaimer 82
No comments:
Post a Comment